Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2007 1
2008 1
2010 2
2011 1
2012 2
2013 2
2015 2
2017 1
2019 2
2020 3
2021 2
2022 1
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Nassiri F, et al. Among authors: yankelevich m. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188783 Free PMC article. Clinical Trial.
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. Yankelevich M, et al. Res Sq [Preprint]. 2023 Nov 9:rs.3.rs-3570311. doi: 10.21203/rs.3.rs-3570311/v1. Res Sq. 2023. Update in: J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744 PMID: 37986911 Free PMC article. Updated. Preprint.
Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma: A work in progress.
Yankelevich M, Zaky W, Lafay-Cousin L, Osorio D, Adamski J, Kordes U, Finlay JL, Prados M, Mueller S. Yankelevich M, et al. Neurooncol Adv. 2024 Jul 5;6(1):vdae109. doi: 10.1093/noajnl/vdae109. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39036438 Free PMC article.
Choroid plexus carcinoma in children: the Head Start experience.
Zaky W, Dhall G, Khatua S, Brown RJ, Ginn KF, Gardner SL, Yildiz VO, Yankelevich M, Finlay JL. Zaky W, et al. Among authors: yankelevich m. Pediatr Blood Cancer. 2015 May;62(5):784-9. doi: 10.1002/pbc.25436. Epub 2015 Feb 8. Pediatr Blood Cancer. 2015. PMID: 25662896
Predictive factors for blood stream infections in children with cancer.
Doganis D, Asmar B, Yankelevich M, Thomas R, Ravindranath Y. Doganis D, et al. Among authors: yankelevich m. Pediatr Hematol Oncol. 2013 Aug;30(5):403-15. doi: 10.3109/08880018.2013.778379. Epub 2013 Mar 22. Pediatr Hematol Oncol. 2013. PMID: 23521175
22 results